NetraMark Holdings Inc. announced that it has signed two contracts with a large publicly listed biopharmaceutical company, pursuant to the previously announced Master Service Agreement on October 31, 2023. NetraMark will employ its proprietary Attractor AI technology to analyze clinical trial data provided from two of the biopharmaceutical company's distinct Phase II candidate medicines. The primary objectives of the contracts are as follows: Enable the generation of novel insights and hypotheses with regards to each study's patient population.

Identify drug and placebo response persona characteristics. Perform adverse event and risk modeling. Output specific hypotheses that inform enrichment and recruitment criteria for upcoming late phase studies.